PASG 股价走势图
PASG 股票价格预测
Passage Bio Inc
$5.03
14.31%
$0.62
收盘价：May 12, 16:00:00 GMT-4
$4.8
-4.57%
$-0.23
盘前：May 13, 08:03:55 GMT-4
返回
Passage Bio Inc (PASG) 股票价格预测
关键数据
前收盘价
$4.4
开盘价
$4.52
当日区间
$4.28 - $5.14
52周范围
$3.93 - $20
交易量
159.2K
平均成交量
77.4K
股息收益率
--
每股收益（TTM）
-14.44
市值
$15.4M
什么是 PASG？
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.
